|Haploidentical BMT appears safe, effective for older patients with hematologic ...|
Nonmyeloablative HLA-haploidentical blood or marrow transplantation followed by cyclophosphamide demonstrated safety and promising survival outcomes for older patients with hematologic malignancies, according to the results of a retrospective analysis.
Healio - Fri, 09 Oct 2015 11:04
|Lymphoma & Myeloma 2015: An International Congress on Hematologic Malignancies ...|
The congress will focus on controversial areas in the management of hematologic malignancies, with international and nationally recognized thought leaders providing expert guidance and analysis of recent developments in basic science, translational ...
Healio - Fri, 02 Oct 2015 07:03
|Lymphoma & Myeloma 2015 Congress Offers Research And Translational Medicine ...|
Lymphoma News Today - Fri, 02 Oct 2015 05:11
|Future Immunotherapies for Hematologic Malignancies|
Future approaches to the management of hematologic malignancies will involve immunotherapy, states Ivan Marques Borrello, MD. Recent immunotherapy agents, such as elotuzumab in multiple myeloma and ipilimumab in melanoma, have induced long-tail ...
OncLive - Thu, 24 Sep 2015 16:05
|Chemotherapy Protects Kidneys in LCDD|
Achieving a hematologic complete response (CR) or very good partial response (VGPR) in LCDD (light chain deposition disease: a "monoclonal gammopathy of renal significance") prolongs renal survival, even if advanced renal impairment has supervened.
MedPage Today - Wed, 07 Oct 2015 11:22
|Biogen Announces Departure of Tony Kingsley|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is ...
MarketWatch - Fri, 09 Oct 2015 04:31
|Company Update: Biogen Idec Inc (NASDAQ:BIIB) - Biogen Announces Departure of ...|
Jutia Group (press release) (blog) - Fri, 09 Oct 2015 08:22
|Genetic testing may improve myeloma risk stratification, treatment|
“Our study has identified genetic features which can identify those patients whose myeloma is likely to prove aggressive and to progress quickly,” Gareth Morgan, MD, professor of hematology at The Institute of Cancer Research, said in a press release.
Healio - Fri, 09 Oct 2015 23:11
|Renal extramedullary hematopoiesis: interstitial and glomerular pathology|
Ten patients died in the follow-up period from their underlying hematological disease and had persistent renal disease. The two remaining patients had persistent chronic kidney disease. Renal extramedullary hematopoiesis should be considered in the ...
Nature.com - Fri, 09 Oct 2015 04:37
|Abstract and Introduction|
Background: Patients with hematologic malignancies often receive aggressive care at the end-of-life. To better understand the end-of-life decision-making process among oncology specialists, we compared the cancer treatment recommendations, and ...
Medscape - Tue, 22 Sep 2015 21:07